Zymeworks (ZYME) Share-based Compensation (2021 - 2026)
Zymeworks' (ZYME) quarterly Share-based Compensation came in at $6.9 million in Q1 2026, up 8.33% year-on-year from $6.4 million in Q1 2025, and down 21.64% quarter-over-quarter from $8.8 million in Q4 2025.
Zymeworks (ZYME) Share-based Compensation (2021 - 2026) Analysis & Trends
Zymeworks has disclosed Share-based Compensation across 6 years of filings, most recently posting $6.9 million for Q1 2026.
- Share-based Compensation for Q1 2026 came in at $6.9 million, up 8.33% year-over-year; the trailing twelve-month figure through Mar 2026 was $28.6 million (up 38.39% YoY), and the FY2025 annual result was $28.0 million, up 57.57% from the prior year.
- Share-based Compensation came in at $6.9 million for Q1 2026 at Zymeworks, down from $8.8 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $8.8 million in Q4 2025 to a low of -$8.2 million in Q1 2022.
- The 5-year median for Share-based Compensation is $4.6 million (2024), against an average of $3.8 million.
- Across the five-year window, Share-based Compensation plunged 87.32% in 2023 and soared 1141.14% in 2024, its largest moves.
- Zymeworks' Share-based Compensation stood at $4.5 million in 2022, then decreased by 25.08% to $3.4 million in 2023, then soared by 48.99% to $5.0 million in 2024, then soared by 76.26% to $8.8 million in 2025, then dropped by 21.64% to $6.9 million in 2026.
- The last three Share-based Compensation figures came in at $6.9 million (Q1 2026), $8.8 million (Q4 2025), and $6.9 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | - |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | 305,000.00 |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 166.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 26.47 Mn |
| 10 | Zymeworks | 1.73 Bn | 1.36 Bn | - | 6.94 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.94 Mn |
| Mar 31, 2026 | 6.94 Mn |
| Dec 31, 2025 | 8.85 Mn |
| Dec 31, 2025 | 8.85 Mn |
| Sep 30, 2025 | 6.91 Mn |
| Sep 30, 2025 | 6.91 Mn |
| Jun 30, 2025 | 5.87 Mn |
| Jun 30, 2025 | 5.87 Mn |
| Mar 31, 2025 | 6.40 Mn |
| Mar 31, 2025 | 6.40 Mn |
| Dec 31, 2024 | 5.02 Mn |
| Dec 31, 2024 | 5.02 Mn |
| Sep 30, 2024 | 4.66 Mn |
| Sep 30, 2024 | 4.66 Mn |
| Jun 30, 2024 | 4.56 Mn |
| Jun 30, 2024 | 4.56 Mn |
| Mar 31, 2024 | 3.55 Mn |
| Mar 31, 2024 | 3.55 Mn |
| Dec 31, 2023 | 3.37 Mn |
| Dec 31, 2023 | 3.37 Mn |